Price Target

Zacks Small-Cap Research initiated coverage on Cosmos Health with a $4.50 price target. They highlight the company’s diversified, vertically integrated model, anticipating strong revenue growth driven by high-margin pharmaceuticals, nutraceuticals, telehealth, and AI R&D. The valuation is based on a five-year DCF analysis, factoring in U.S. market expansion, a $300 million financing facility, and digital asset strategy. Zacks also noted positive recent financial performance.

Analysts boosted AMD’s stock to ‘buy’ with a $200 target, citing its MI350 AI chips as a strong Nvidia competitor. Increased optimism centers on the MI350’s performance rivaling Nvidia’s Blackwell and higher-than-expected pricing, with the MI355 model now projected to sell for $25,000. HSBC significantly raised AMD’s projected 2026 AI chip revenue to $15.1 billion (up from $9.6B). The positive outlook drove AMD’s stock up 4.15% recently.

Nvidia’s market cap has reached $3.77 trillion, making it the world’s most valuable company. Loop Capital analyst Ananda Baruah forecasts a $6 trillion market cap, setting a $250 per share price target, driven by the “golden wave” of AI adoption. He projects $2 trillion in spending on AI by 2028, with hyperscale cloud providers shifting to non-CPU computing (50-60% by year-end) and the upcoming Blackwell chip production fueling further growth.